Assessment of Steatosis and Fibrosis in Liver Transplant Recipients Using Controlled Attenuation Parameter and Liver Stiffness Measurements

Table 4

Univariate and multivariate analysis of predictors of severe steatosis (elevated CAP ≥290 dB).

Variables	Univariate		Multivariate
	OR (95% CI)	value	OR (95% CI)	value
Age at LT, years	1.02 (0.99–1.05)	0.115
Age at TE, years	1.03 (1.01–1.06)	0.049	1.01 (0.96–1.07)	0.494
Donor age, years	0.99 (0.97–1.02)	0.574
Gender (female ref.)	1.48 (0.77–2.82)	0.240
Cause of liver disease
Autoimmune liver disease	0.64 (0.24–1.71)	0.372	1.52 (0.91–1.83)	0.984
Alcoholic liver disease	1.99 (1.04–3.80)	0.038
HCV	1.15 (0.23–5.88)	0.863
Others	0.61 (0.33–1.11)	0.108
BMI, kg/m^2	1.10 (1.01–1.20)	0.042	2.77 (1.34–3.85)	0.048
Donors BMI, kg/m^2	1.01 (0.93–1.09)	0.836
Hypertension	0.10 (0.01–1.54)	0.100
Diabetes	2.64 (1.41–4.95)	0.002	1.48 (1.21–1.85)	0.044
Thrombocytes x10^9/L	0.99 (0.98–1.01)	0.621
Glucose, mmol/L	1.21 (1.02–1.45)	0.033	1.11 (0.95–1.30)	0.368
Total bilirubin, mmol/L	1.01 (0.98–1.04)	0.718
ALT, U/L	1.01 (0.99–1.02)	0.534
AST, U/L	1.01 (0.99–1.02)	0.309
GGT, U/L	1.01 (0.98–1.02)	0.184
Triglyceride, mmol/L	1.79 (1.18–2.69)	0.006	1.63 (1.15–2.59)	0.041
Total cholesterol, mmol/L	1.23 (0.93–1.63)	0.146
LDL, mmol/L	1.19 (0.86–1.66)	0.290
HDL, mmol/L	0.60 (0.27–1.34)	0.209
CRP, mg/L	0.99 (0.97–1.02)	0.770
LSM, kPa	1.02 (0.97–1.07)	0.410
Time from LT to TE, years	1.09 (0.98–1.23)	0.104

LT, liver transplantation; NAFLD, nonalcoholic fatty liver disease; HCV, hepatitis C virus infection; BMI, body mass index; AST, serum aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; CRP, C-reactive protein; LSM, liver stiffness measurement; TE, transient elastography.